United States Antipsychotic Drugs Market 2033 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Antipsychotic Drugs Market size reached US$ 16.41 Billion in 2024 and is expected to reach US$ 36.05 Billion by 2033, growing at a CAGR of 9.2% during the forecast period 2025-2033, according to DataM Intelligence report.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/antipsychotic-drugs-market?sb

Key Development:

United States: Recent Antipsychotic Drug Developments

✅ In December 2025, Newron Pharmaceuticals advanced strategic investor and partnering discussions around its antipsychotic pipeline, strengthening industry engagement for treatment-resistant schizophrenia therapies. The move supports future collaborations and late-stage development momentum. It reflects growing focus on differentiated CNS treatments.

✅ In September 2025, Newron initiated the ENIGMA-TRS-2 Phase III clinical trial in the U.S. evaluating evenamide as an add-on therapy for treatment-resistant schizophrenia. The study follows regulatory and ethics approvals. It marks a key late-stage milestone for a novel antipsychotic mechanism.

✅ In July 2025, Johnson & Johnson submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for CAPLYTA® (lumateperone) for schizophrenia relapse prevention. The submission was supported by Phase III clinical data. It expands the regulatory scope of an approved atypical antipsychotic.

✅ In July 2025, CAPLYTA® entered FDA review based on data demonstrating significantly longer time to relapse versus placebo. The development strengthens clinical positioning in long-term schizophrenia management. It underscores continued innovation in oral antipsychotic therapies.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=antipsychotic-drugs-market

Japan: Recent Antipsychotic Drug Developments

✅ In December 2025, Otsuka Pharmaceutical reported continued CNS pipeline prioritization, reinforcing long-term R&D focus in psychiatric and antipsychotic treatments. The activity highlights Japan's sustained investment in mental health innovation. It supports future clinical and regulatory initiatives.

✅ In November 2025, Otsuka advanced regulatory activity across its CNS portfolio, signaling momentum that supports antipsychotic lifecycle management and pipeline expansion. The developments strengthen Japan's global psychiatry drug presence. It reflects ongoing commitment to neuropsychiatric therapies.

✅ In September 2025, Otsuka and Lundbeck received regulatory feedback related to brexpiprazole-based therapies, a molecule widely used in antipsychotic treatment. The update marked an important regulatory milestone. It informs next steps in clinical and commercial strategy.

✅ In October 2025, Sumitomo Pharma expanded support and availability for long-acting injectable antipsychotic therapies in Japan. The initiative improves adherence-focused schizophrenia treatment options. It strengthens Japan's position in long-acting CNS drug delivery.

Key Players:

=> Bayer AG, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin, Cipla, Sanofi, AdvaCare Pharma, Wellona Pharma, and Montage Laboratories Pvt. Ltd, among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/antipsychotic-drugs-market?sb

Key Segments:

By Type

Second Generation Antipsychotics dominate the market with approximately 55% share, driven by their improved safety profile, lower risk of extrapyramidal side effects, and broader use across multiple psychiatric disorders. These drugs are widely prescribed due to better patient compliance and expanded indications.
First Generation Antipsychotics account for around 25%, supported by their continued use in acute psychosis management and cost-effectiveness, particularly in developing regions.
Third Generation Antipsychotics represent 20%, driven by growing adoption of dopamine partial agonists, rising awareness of personalized mental health treatments, and ongoing product innovations.

By Indication

Schizophrenia holds the largest share at approximately 40%, driven by the high prevalence of the disorder and long-term dependence on antipsychotic pharmacotherapy.
Bipolar Disorder accounts for 25%, supported by the increasing use of antipsychotics in managing manic and mixed episodes.
Dementia-related psychosis represents 15%, driven by the aging population and rising incidence of neurodegenerative diseases.
Depression holds 10%, supported by off-label use and combination therapy approaches.
Others account for 10%, including anxiety-related psychosis and behavioral disorders.

By Route of Administration

Oral Antipsychotics dominate with nearly 65% share, driven by ease of administration, wide availability of formulations, and strong patient adherence for long-term treatment.
Parenteral Antipsychotics account for 35%, supported by rising adoption of long-acting injectable (LAI) formulations for improved compliance, relapse prevention, and reduced hospitalization rates.

By Region

North America - 38% Share
North America leads the market due to high diagnosis rates, strong reimbursement frameworks, advanced psychiatric care infrastructure, and widespread adoption of second- and third-generation antipsychotics.

Europe - 27% Share
Europe accounts for 27%, supported by government-funded mental health programs, increasing awareness of psychiatric disorders, and strong presence of major pharmaceutical manufacturers.

Asia Pacific - 22% Share
Asia Pacific holds 22%, driven by a growing mental health patient population, improving access to psychiatric care, and increasing investments in healthcare infrastructure.

Latin America - 7% Share
Latin America represents 7%, supported by expanding mental health initiatives and gradual improvement in diagnosis and treatment rates.

Middle East and Africa - 6% Share
Middle East and Africa account for 6%, driven by rising awareness of mental health conditions, healthcare modernization efforts, and increasing access to essential psychotropic medications.

FAQ

What is the current size of the Antipsychotic Drugs Market?

A: In 2024, the Antipsychotic Drugs Market was valued at US$ 16.41 Billion, reflecting its strong industry presence.

Q2: How large is the Antipsychotic Drugs Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Antipsychotic Drugs Market will grow to around US$ 36.05 Billion , demonstrating significant expansion.

Q3: What is the growth rate of the Antipsychotic Drugs Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 9.2% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.